Loading: 100%
INTERCEPT PHARMACEUTICALS INC logo
no logo available
General Information
Investor relations pageIR page no data available
Founding year no data available
Headquarter , , no data available
Employees 456 (as per Q1 2016)no data available
Sector Biotechnology, HealthcareBiotechnology, Healthcareno data available
Ticker ICPTno data available
Financial year endsFY ends End of Decemberno data available
Stock Information (historical prices adjusted for splits and dividends)
Adj. Closing prices (in USD) -Common sharesNov. 16Jan. 17März 17Mai 17Juli 17Sep. 1704080120160
datesClosing price (adj.)
13.10.201765.49
11.10.201767.57
04.10.201768.73
27.09.201757.01
20.09.201798.12
13.09.201790.75
06.09.2017117.61
30.08.2017114.10
23.08.2017106.94
16.08.2017105.47
09.08.2017103.02
02.08.2017105.00
26.07.2017128.82
19.07.2017126.31
12.07.2017128.16
05.07.2017124.28
27.06.2017122.01
20.06.2017125.00
13.06.2017119.41
06.06.2017119.71
30.05.2017108.52
23.05.2017112.99
16.05.2017119.59
09.05.2017116.48
02.05.2017115.14
25.04.2017114.77
18.04.2017106.68
11.04.2017108.58
04.04.2017112.37
28.03.2017115.79
21.03.2017116.01
14.03.2017121.84
07.03.2017121.68
28.02.2017127.59
21.02.2017125.45
14.02.2017126.96
07.02.2017113.57
31.01.2017109.75
24.01.2017105.40
17.01.2017113.63
10.01.2017105.66
03.01.2017102.95
27.12.2016103.89
19.12.2016109.89
12.12.2016107.19
05.12.2016103.24
28.11.2016108.71
21.11.2016115.32
14.11.2016113.91
07.11.2016100.66
31.10.2016123.74
24.10.2016131.87
17.10.2016138.48
no share price data source found
Share price data requested
Key Figures
Last Closing Price
as per Oct 13, 2017, in USD
65.49n/a
Market Capitalisation
in million USD
1,611n/a
Enterprise Value
in million USD
3,855n/a
Common Shares Outstanding
as per Apr 15, 2016
24,595,270n/a
Preferred Shares Outstanding
as per Apr 15, 2016
42,777,778n/a
Average Basic Shares Outstanding
TTM
24,274,959n/a
Average Diluted Shares Outstanding
TTM
n/a
Index Membership
n/a
Business Summary
Intercept Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases with high unmet medical need.
no data available
Key Financials & Ratios (all figures TTM as per , million USD, full statements further below)
Profit & Loss
Revenues 0n/a
Gross Profit 0n/a
Operating Income 0n/a
EBITDA 0n/a
Net Profit 0n/a
Balance Sheet
Cash and Cash Equivalents 557n/a
Receivables 0n/a
Total Current Assets 575n/a
PP&E 12n/a
Total Assets 593n/a
Accounts Payable 42n/a
Current Debt 0n/a
Total Current Liabilities 99n/a
Long-Term Debt 0n/a
Total Liabilities 105n/a
Total Equity 488n/a
Cash Flow
Depreciation & Amortisation 2n/a
Change in Working Capital 67n/a
Operating Cash Flow -203n/a
Net Change in PP&E and Intangibles -6n/a
Investing Cash Flow -224n/a
Dividends Paid 0n/a
Financing Cash Flow 372n/a
Total Change in Cash -55n/a
Free Cash Flow 0n/a
Profitability Ratios
Gross Margin 0.0%n/a
Operating Margin 0.0%n/a
Net Profit Margin 0.0%n/a
Return on Equity 0.0%n/a
Return on Assets 0.0%n/a
Per Share Figures
Basic EPS n/a
Diluted EPS n/a
Sales per Share n/a
Book Value per Share 20.12n/a
FCF per Share n/a
Dividends per Share 0.00n/a
Price Multiples
Price to Earnings Ratio n/a
Price to Sales Ratio n/a
Price to Book Value 3.26n/a
Price to Free Cash Flow n/a
Valuation Metrics
EV/EBITDA n/a
EV/Sales n/a
Book to Market Value 0.30n/a
Other Ratios
Current Ratio 579.3%n/a
Liabilities to Equity Ratio 21.5%n/a
Debt to Assets Ratio 0.0%n/a
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15
Revenue
0
2
2
2
2
3
Sales & Services Revenue
0
0
0
0
0
0
Financing Revenue
0
0
0
0
0
0
Other Revenue
0
0
0
0
0
0
Cost of revenue
0
0
0
0
0
0
Cost of Goods & Services
0
0
0
0
0
0
Cost of Financing Revenue
0
0
0
0
0
0
Cost of Other Revenue
0
0
0
0
0
0
Gross Profit
0
2
2
2
2
3
Other Operating Income
0
0
0
0
0
0
Operating Expenses
-16
-16
-21
-41
-114
-229
Selling, General & Administrative
-4
-4
-5
-13
-35
-104
Selling & Marketing
0
0
0
0
0
0
General & Administrative
0
0
0
0
0
0
Research & Development
-13
-11
-16
-28
-80
-128
Depreciation & Amortization
0
0
0
0
0
0
Provision For Doubtful Accounts
0
0
0
0
0
0
Other Operating Expense
0
0
0
0
1
3
Operating Income (Loss)
-16
-14
-19
-39
-112
-226
Non-Operating Income (Loss)
1
1
-25
-28
-170
3
Interest Expense, net
0
0
0
0
0
0
Interest Expense
0
0
0
0
0
0
Interest Income
0
0
0
0
0
0
Other Investment Income (Loss)
0
0
0
0
0
0
Foreign Exchange Gain (Loss)
0
0
0
0
0
0
Income (Loss) from Affiliates
0
0
0
0
0
0
Other Non-Operating Income (Loss)
0
0
0
0
0
0
Pretax Income (Loss), Adjusted
-15
-13
-44
-68
-282
-224
Abnormal Gains (Losses)
-1
1
25
28
171
0
Acquired In-Process R&D
0
0
0
0
0
0
Merger / Acquisition Expense
0
0
0
0
0
0
Abnormal Derivatives
0
0
0
0
0
0
Disposal of Assets
0
0
0
0
0
0
Early extinguishment of Debt
0
0
0
0
0
0
Asset Write-Down
0
0
0
0
0
0
Impairment of Goodwill & Intangibles
0
0
0
0
0
0
Sale of Business
0
0
0
0
0
0
Legal Settlement
0
0
0
0
0
0
Restructuring Charges
0
0
0
0
0
0
Sale of and Unrealized Investments
0
0
0
0
0
0
Insurance Settlement
0
0
0
0
0
0
Other Abnormal Items
0
0
0
0
0
0
Pretax Income (Loss)
-16
-12
-19
-39
-112
-224
Income Tax (Expense) Benefit, net
0
0
0
0
0
0
Current Income Tax
0
0
0
0
0
0
Deferred Income Tax
0
0
0
0
0
0
Tax Allowance/Credit
0
0
0
0
0
0
Income (Loss) from Affiliates, net of taxes
0
0
0
0
0
0
Income (Loss) from Continuing Operations
-16
-12
-19
-39
-112
-224
Net Extraordinary Gains (Losses)
0
0
0
0
0
0
Discontinued Operations
0
0
0
0
0
0
XO & Accounting Charges & Other
0
0
0
0
0
0
Income (Loss) Including Minority Interest
-16
-12
-19
-39
-112
-224
Minority Interest
0
0
0
0
0
0
Net Income
-16
-12
-19
-39
-112
-224
Preferred Dividends
-3
-3
-3
0
0
0
Other Adjustments
0
0
0
0
0
0
Net Income Available to Common Shareholders
-19
-15
-21
-39
-112
-224
Remarks
restated on Apr 1, 2013 n/a
calculated values,
restated on Mar 14, 2014 n/a
calculated values,
restated on Mar 2, 2015 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
Balance SheetBS data quality: 94% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15
Assets
Cash, Cash Equivalents & Short Term Investments
n/a
18
110
145
240
628
Cash & Cash Equivalents
n/a
18
46
13
20
33
Short Term Investments
n/a
0
65
131
220
595
Accounts & Notes Receivable
n/a
0
0
0
0
0
Accounts Receivable, Net
n/a
0
0
0
0
0
Notes Receivable, Net
n/a
0
0
0
0
0
Unbilled Revenues
n/a
0
0
0
0
0
Inventories
n/a
0
0
0
0
0
Raw Materials
n/a
0
0
0
0
0
Work In Process
n/a
0
0
0
0
0
Finished Goods
n/a
0
0
0
0
0
Other Inventory
n/a
0
0
0
0
0
Other Short Term Assets
n/a
1
2
3
6
14
Prepaid Expenses
n/a
1
2
3
6
14
Derivative & Hedging Assets
n/a
0
0
0
0
0
Assets Held-for-Sale
n/a
0
0
0
0
0
Deferred Tax Assets
n/a
0
0
0
0
0
Income Taxes Receivable
n/a
0
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
Miscellaneous Short Term Assets
n/a
0
0
0
0
0
Total Current Assets
n/a
19
112
148
246
642
Property, Plant & Equipment, Net
n/a
0
0
2
6
10
Property, Plant & Equipment
n/a
0
0
0
0
0
Accumulated Depreciation
n/a
0
0
0
0
0
Long Term Investments & Receivables
n/a
0
0
0
0
0
Long Term Investments
n/a
0
0
0
0
0
Long Term Marketable Securities
n/a
0
0
0
0
0
Long Term Receivables
n/a
0
0
0
0
0
Other Long Term Assets
n/a
0
0
1
2
4
Intangible Assets
n/a
0
0
0
0
0
Goodwill
n/a
0
0
0
0
0
Other Intangible Assets
n/a
0
0
0
0
0
Prepaid Expense
n/a
0
0
0
0
0
Deferred Tax Assets
n/a
0
0
0
0
0
Derivative & Hedging Assets
n/a
0
0
0
0
0
Prepaid Pension Costs
n/a
0
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
Investments in Affiliates
n/a
0
0
0
0
0
Miscellaneous Long Term Assets
n/a
0
0
1
2
4
Total Noncurrent Assets
n/a
1
0
3
8
14
Total Assets
n/a
19
112
150
254
656
Liabilities and owners' equity
Payables & Accruals
n/a
2 1504198
4 3745773
7 7259805
13 13459000
46 45591000
Accounts Payable
n/a
2 1504198
4 3745773
7 7259805
13 13459000
46 45591000
Accrued Taxes
n/a
0 0
0 0
0 0
0 0
0 0
Interest & Dividends Payable
n/a
0 0
0 0
0 0
0 0
0 0
Other Payables & Accruals
n/a
0 0
0 0
0 0
0 0
0 0
Short Term Debt
n/a
0 81762
0 0
0 0
0 0
0 0
Short Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
Short Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
Current Portion of Long Term Debt
n/a
0 0
0 0
0 0
0 0
0 0
Other Short Term Liabilities
n/a
2 2446107
9 9218281
2 1621622
2 1782000
2 1782000
Deferred Revenue
n/a
2 2446107
2 1621622
2 1621622
2 1782000
2 1782000
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
0 0
Deferred Tax Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
Miscellaneous Short Term Liabilities
n/a
0 0
8 7596659
0 0
0 0
0 0
Total Current Liabilities
n/a
4 4032067
13 12964054
9 8881427
15 15241000
47 47373000
Long Term Debt
n/a
0 0
0 0
0 0
0 0
0 0
Long Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
Long Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
Other Long Term Liabilities
n/a
18 17998040
33 33302678
59 59031053
8 8017000
6 6236000
Accrued Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
Pension Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
Pensions
n/a
0 0
0 0
0 0
0 0
0 0
Other Post-Retirement Benefits
n/a
0 0
0 0
0 0
0 0
0 0
Deferred Compensation
n/a
0 0
0 0
0 0
0 0
0 0
Deferred Revenue
n/a
12 12162163
11 10540543
9 8918916
8 8017000
6 6236000
Deferred Tax Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
Miscellaneous Long Term Liabilities
n/a
6 5835877
23 22762135
50 50112137
0 0
0 0
Total Noncurrent Liabilities
n/a
18 17998040
33 33302678
59 59031053
8 8017000
6 6236000
Total Liabilities
n/a
22 22030107
46 46266732
68 67912480
23 23258000
54 53609000
Preferred Equity
n/a
0 0
0 0
0 0
0 0
0 0
Share Capital & Additional Paid-In Capital
n/a
72 72137223
184 184116666
268 268322007
700 700376000
1,300 1300032000
Common Stock
n/a
0 0
0 0
0 0
0 0
0 0
Additional Paid in Capital
n/a
0 0
0 0
0 0
0 0
0 0
Other Share Capital
n/a
0 0
0 0
0 0
0 0
0 0
Treasury Stock
n/a
0 0
0 0
0 0
0 0
0 0
Retained Earnings
n/a
-75 -74540279
-118 -118183350
-186 -185975760
-469 -469202000
-696 -695630000
Other Equity
n/a
0 -184500
0 -21451
0 59853
0 -284000
-2 -2253000
Equity Before Minority Interest
n/a
-3 -2587556
66 65911865
82 82406100
231 230890000
602 602149000
Minority Interest
n/a
0 0
0 0
0 0
0 0
0 0
Total Equity
n/a
-3 -2587556
66 65911865
82 82406100
231 230890000
602 602149000
Total Liabilities & Equity
n/a
19 19442551
112 112178597
150 150318580
254 254148000
656 655758000
Remarks restated on n/a restated on Apr 1, 2013 n/a restated on Mar 14, 2014 n/a restated on Mar 2, 2015 n/a restated on Feb 29, 2016 n/a restated on May 10, 2016 n/a
Cash Flow StatementCF data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15
Net Income/Starting Line
-15
-13
-44
-68
-283
-226
Net Income
0
0
0
0
0
0
Net Income From Discontinued Operations
0
0
0
0
0
0
Other Adjustments
0
0
0
0
0
0
Depreciation & Amortization
0
0
0
0
0
2
Non-Cash Items
1
1
28
40
194
40
Stock-Based Compensation
0
0
0
0
0
0
Deferred Income Taxes
0
0
0
0
0
0
Other Non-Cash Adjustments
0
0
0
0
0
0
Change in Working Capital
0
14
-1
0
1
21
(Increase) Decrease in Accounts Receivable
0
0
0
0
0
0
(Increase) Decrease in Inventories
0
0
0
0
0
0
Increase (Decrease) in Accounts Payable
0
0
0
0
0
0
Increase (Decrease) in Other
0
0
0
0
0
0
Net Cash From Discontinued Operations (operating)
0
0
0
0
0
0
Cash from Operating Activities
-14
3
-16
-28
-88
-163
Change in Fixed Assets & Intangibles
0
0
0
-2
-5
-6
Disposition of Fixed Assets & Intangibles
0
0
0
0
0
0
Disposition of Fixed Assets
0
0
0
0
0
0
Disposition of Intangible Assets
0
0
0
0
0
0
Acquisition of Fixed Assets & Intangibles
0
0
0
0
0
0
Purchase of Fixed Assets
0
0
0
0
0
0
Acquisition of Intangible Assets
0
0
0
0
0
0
Other Change in Fixed Assets & Intangibles
0
0
0
0
0
0
Net Change in Long Term Investment
0
0
-65
-69
-92
-384
Decrease in Long Term Investment
0
0
0
0
0
0
Increase in Long Term Investment
0
0
0
0
0
0
Net Cash From Acquisitions & Divestitures
0
0
0
0
0
0
Net Cash from Divestitures
0
0
0
0
0
0
Cash for Acqusition of Subsidiaries
0
0
0
0
0
0
Cash for Joint Ventures
0
0
0
0
0
0
Net Cash from Other Acquisitions
0
0
0
0
0
0
Other Investing Activities
0
0
0
0
0
0
Net Cash From Discontinued Operations (investing)
0
0
0
0
0
0
Cash from Investing Activities
0
0
-65
-70
-97
-389
Dividends Paid
0
0
0
0
0
0
Cash From (Repayment of) Debt
0
0
0
0
0
0
Cash From (Repayment of) Short Term Debt, net
0
0
0
0
0
0
Cash From (Repayment of) Long Term Debt, net
0
0
0
0
0
0
Repayments of Long Term Debt
0
0
0
0
0
0
Cash From Long Term Debt
0
0
0
0
0
0
Cash From (Repurchase of) Equity
25
0
108
66
191
565
Increase in Capital Stock
25
0
108
66
191
565
Decrease in Capital Stock
0
0
0
0
0
0
Other Financing Activities
0
0
0
0
0
0
Net Cash From Discontinued Operations (financing)
0
0
0
0
0
0
Cash from Financing Activities
25
0
108
66
191
565
Net Cash Before Disc. Operations and FX
11
2
28
-32
7
13
Change in Cash from Disc. Operations and Other
0
0
0
0
0
0
Net Cash Before FX
11
2
28
-32
7
13
Effect of Foreign Exchange Rates
0
0
0
0
0
0
Net Changes in Cash
11
2
28
-32
7
13
Remarks
restated on Apr 1, 2013 n/a
calculated values,
restated on Mar 14, 2014 n/a
calculated values,
restated on Mar 2, 2015 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
restated on Feb 29, 2016 n/a
calculated values,
Some of the data shown on this page is provided for free by IEX
Sumo